Pharsight

Tygacil patents expiration

TYGACIL's oppositions filed in EPO
TYGACIL Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9254328 PF PRISM CV Tigecycline compositions and methods of preparation
Mar, 2026

(2 years from now)

US9694078 PF PRISM CV Tigecycline compositions and methods of preparation
Mar, 2026

(2 years from now)

US10588975 PF PRISM CV Tigecycline compositions and methods of preparation
Mar, 2026

(2 years from now)

US8975242 PF PRISM CV Tigecycline compositions and methods of preparation
Oct, 2028

(5 years from now)

US7879828 PF PRISM CV Tigecycline compositions and methods of preparation
Feb, 2029

(5 years from now)

US8372995 PF PRISM CV Crystalline solid forms of tigecycline and methods of preparing same
Oct, 2030

(7 years from now)

Tygacil is owned by Pf Prism Cv.

Tygacil contains Tigecycline.

Tygacil has a total of 6 drug patents out of which 0 drug patents have expired.

Tygacil was authorised for market use on 15 June, 2005.

Tygacil is available in powder;intravenous dosage forms.

The generics of Tygacil are possible to be released after 08 October, 2030.

Drugs and Companies using TIGECYCLINE ingredient

Market Authorisation Date: 15 June, 2005

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

TYGACIL family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic